Your browser is no longer supported. Please, upgrade your browser.
SRNE Sorrento Therapeutics, Inc. monthly Stock Chart
SRNE [NASD]
Sorrento Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.72 Insider Own34.21% Shs Outstand182.61M Perf Week-1.38%
Market Cap1.03B Forward P/E- EPS next Y-0.93 Insider Trans0.06% Shs Float147.65M Perf Month120.26%
Income-249.20M PEG- EPS next Q-0.23 Inst Own16.40% Short Float15.98% Perf Quarter126.24%
Sales33.00M P/S31.14 EPS this Y-14.80% Inst Trans7.38% Short Ratio0.92 Perf Half Y76.68%
Book/sh0.55 P/B9.09 EPS next Y-5.00% ROA-44.50% Target Price- Perf Year77.94%
Cash/sh- P/C- EPS next 5Y37.00% ROE-322.50% 52W Range1.39 - 10.00 Perf YTD47.93%
Dividend- P/FCF- EPS past 5Y-11.10% ROI-91.30% 52W High-50.00% Beta3.00
Dividend %- Quick Ratio0.50 Sales past 5Y52.40% Gross Margin62.50% 52W Low259.71% ATR0.80
Employees310 Current Ratio0.60 Sales Q/Q26.20% Oper. Margin- RSI (14)61.51 Volatility9.27% 20.52%
OptionableYes Debt/Eq1.98 EPS Q/Q59.60% Profit Margin- Rel Volume0.49 Prev Close5.05
ShortableYes LT Debt/Eq1.81 EarningsMar 27 AMC Payout- Avg Volume25.53M Price5.00
Recom2.00 SMA2024.16% SMA5067.78% SMA20086.61% Volume12,568,434 Change-0.99%
May-26-20Initiated Dawson James Buy $24
Oct-07-19Initiated JMP Securities Mkt Outperform $21
Jun-28-18Initiated B. Riley FBR, Inc. Buy $14.25
Jan-16-18Reiterated H.C. Wainwright Buy $20 → $30
May-22-17Reiterated Rodman & Renshaw Buy $30 → $20
May-22-17Reiterated FBR & Co. Outperform $13 → $9
Oct-03-16Initiated ROTH Capital Buy
Apr-06-16Reiterated FBR Capital Outperform $21 → $16
Mar-16-16Reiterated FBR Capital Outperform $22 → $21
Dec-22-15Initiated FBR Capital Outperform $22
Dec-07-15Resumed Rodman & Renshaw Buy $45
Aug-03-15Resumed MLV & Co Buy $34
Jul-29-15Reiterated Brean Capital Buy $17 → $26
May-28-15Initiated Brean Capital Buy $17
Mar-17-15Reiterated H.C. Wainwright Buy $13 → $20
Oct-02-14Initiated H.C. Wainwright Buy $11
Jun-19-14Initiated MLV & Co Buy $9
Dec-03-13Initiated Aegis Capital Buy $40
Nov-21-13Initiated CRT Capital Buy $11
Jun-01-20 06:10PM  
02:05PM  
12:55PM  
09:18AM  
May-29-20 03:10PM  
02:55PM  
11:40AM  
May-28-20 06:41PM  
04:39PM  
02:00PM  
01:50PM  
01:00PM  
11:15AM  
11:00AM  
09:21AM  
May-27-20 09:05PM  
07:00PM  
06:40PM  
06:00PM  
04:46PM  
03:30PM  
03:10PM  
03:10PM  
02:39PM  
01:45PM  
12:41PM  
11:35AM  
10:56AM  
07:28AM  
May-26-20 04:53PM  
04:42PM  
04:34PM  
01:01PM  
12:03PM  
09:00AM  
May-25-20 03:00PM  
May-23-20 09:15AM  
08:00AM  
May-22-20 05:18PM  
03:15PM  
May-21-20 07:00AM  
May-20-20 01:18PM  
01:04PM  
12:21PM  
11:52AM  
10:13AM  
07:02AM  
May-19-20 07:37PM  
07:02AM  
May-18-20 03:18PM  
02:36PM  
02:05PM  
01:35PM  
10:11AM  
08:36AM  
May-16-20 08:41AM  
May-15-20 04:13PM  
01:45PM  
11:57AM  
11:53AM  
11:00AM  
10:49AM  
10:24AM  
May-13-20 12:30PM  
May-08-20 11:51AM  
11:09AM  
Apr-15-20 08:52AM  
Apr-08-20 02:54PM  
Apr-02-20 12:33PM  
Apr-01-20 10:25AM  
Mar-31-20 02:01PM  
Mar-25-20 10:00AM  
Mar-24-20 09:32AM  
Mar-23-20 09:30AM  
09:00AM  
Mar-20-20 09:25AM  
07:00AM  
Mar-13-20 12:30PM  
Mar-05-20 09:13AM  
Mar-03-20 10:45AM  
Feb-27-20 03:30PM  
06:00AM  
Feb-21-20 09:15AM  
Jan-29-20 07:00AM  
Jan-27-20 12:21PM  
08:45AM  
07:00AM  
07:00AM  
Jan-10-20 10:59AM  
10:29AM  
09:03AM  
08:30AM  
07:00AM  
Jan-06-20 07:00AM  
Dec-16-19 07:00AM  
Dec-09-19 07:00AM  
Dec-03-19 04:14PM  
Nov-27-19 08:51AM  
03:32AM  
Nov-26-19 11:25AM  
Sorrento Therapeutics, Inc., a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches. It also offers Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. In addition, the company's clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases. Further, it develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Additionally, the company engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. It has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection, as well as a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento's COVID-19 therapeutic product candidates. The company was founded in 2006 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smith Robin LDirectorMar 05Buy2.2740,00090,89660,000Mar 05 01:58 PM